Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FOLFOXIRI plus Cetuximab in Metastatic Colorectal Cancer
NCT00689624Phase 2Completed
- Sponsor
- University Hospital of Crete
- Start
- Jul 2007
- Primary completion
- Dec 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of KL-140 in metastatic colorectal cancer (mCRC), sponsored by University Hospital of Crete. Primary endpoint: Objective Response Rate at 2 months. Started Jul 2007; status: completed.
02
Drugs
KL-140
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT00689624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00689624.